Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen in HIV-1 infection: a guide to its use in the EU
Drugs and Therapy Perspectives, ISSN: 1179-1977, Vol: 31, Issue: 8, Page: 251-258
2015
- 3Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures3
- Readers3
Article Description
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (tenofovir DF) [Eviplera® (EU); Complera® (USA)] is a convenient and effective addition to the other single-tablet regimens currently available for the treatment of HIV-1 infection. Once-daily emtricitabine/rilpivirine/tenofovir DF was noninferior to once-daily emtricitabine/efavirenz/tenofovir DF in establishing virological suppression in treatment-naïve adults. Switching to the once-daily single tablet maintained virological suppression and was noninferior to remaining on a more complex multiple-tablet regimen in treatment-experienced patients already virologically suppressed with an antiretroviral regimen and without prior virological failure. Emtricitabine/rilpivirine/tenofovir DF was generally well tolerated, with a more favourable overall tolerability profile than emtricitabine/efavirenz/tenofovir DF.
Bibliographic Details
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know